Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1735844

Cover Image

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1735844

Global Hydroxyzine Market Size study, by Dosage Form, Route of Administration, Indication, Distribution Channel and Regional Forecasts 2022-2032

PUBLISHED:
PAGES: 285 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (Enterprise License)
USD 6250

Add to Cart

Global Hydroxyzine Market is valued approximately at USD 0.78 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.40% over the forecast period 2024-2032. Hydroxyzine, a first-generation antihistamine, continues to play a pivotal role in managing allergic skin conditions and anxiety-related symptoms due to its potent sedative and antipruritic effects. Originally introduced for urticaria and histamine-mediated pruritus, hydroxyzine has found extended utility in dermatology and psychiatry, making it a clinically flexible and cost-effective therapeutic option. As clinicians strive to mitigate patient discomfort linked with chronic itching and allergic inflammation, hydroxyzine is increasingly favored for its dual-action pharmacology-addressing both psychological and physiological contributors to dermatoses.

The growing incidence of atopic dermatitis and other allergy-induced conditions globally is one of the primary forces driving the demand for hydroxyzine-based formulations. Pharmaceutical manufacturers are expanding dosage availability to accommodate different demographics, especially in pediatric and geriatric segments. From tablets and capsules to syrup formulations, tailored delivery formats are gaining traction to ensure higher patient compliance. Furthermore, the rise of generic drug production post-patent expiration has catalyzed broader market penetration, particularly in low-to-middle-income countries. Enhanced access and affordability are also being augmented by government-backed healthcare subsidies and favorable formulary inclusions.

On the flip side, market growth is occasionally stifled by concerns related to hydroxyzine's sedative properties and central nervous system side effects. Regulatory bodies in some regions have issued usage guidelines, especially for elderly patients or those concurrently on CNS depressants. Nonetheless, technological innovation in drug delivery and an increasing inclination towards personalized medicine are helping to mitigate safety concerns. Continued pharmacovigilance and real-world data analytics are supporting more refined prescribing protocols while expanding the indications of hydroxyzine to include adjunctive therapy in anxiety and sleep disorders.

Digitally enabled distribution models-particularly through online pharmacies and telehealth providers-are transforming accessibility and awareness for antihistamine medications like hydroxyzine. Direct-to-patient platforms now allow for remote diagnosis and prescription fulfillment, bridging gaps in dermatological and psychiatric care in rural and underserved areas. Moreover, hospitals and specialty clinics are collaborating with retail chains to ensure seamless drug availability through integrated supply chains. These improvements in pharmaceutical logistics are significantly supporting both acute and chronic therapeutic regimens involving hydroxyzine.

Regionally, North America holds the lion's share of the hydroxyzine market due to widespread allergic conditions, robust insurance coverage, and a well-established clinical adoption of antihistamines in both outpatient and emergency care settings. Europe follows suit, where countries like Germany, France, and the UK demonstrate high prescription rates driven by seasonal allergy spikes and a growing geriatric population. Asia Pacific is anticipated to showcase the highest CAGR, spurred by increasing awareness of skin health, expanding pharmaceutical distribution, and government initiatives to curb allergic disease burdens. Latin America and the Middle East & Africa are also emerging as significant contributors as healthcare infrastructure and dermatological diagnostics improve steadily.

Major market player included in this report are:

  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Pfizer Inc.
  • Cipla Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Glenmark Pharmaceuticals Ltd.
  • Aurobindo Pharma Ltd.
  • Mylan N.V.
  • Apotex Inc.
  • Hikma Pharmaceuticals PLC
  • Torrent Pharmaceuticals Ltd.
  • Taro Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Zydus Lifesciences Ltd.

The detailed segments and sub-segment of the market are explained below:

By Dosage Form

  • Tablets
  • Capsules
  • Injections
  • Syrups

By Route of Administration

  • Oral
  • Intramuscular

By Indication

  • Urticaria
  • Atopic Contact Dermatitis
  • Histamine-mediated Pruritus

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Years considered for the study are as follows:

  • Historical year: 2022
  • Base year: 2023
  • Forecast period: 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with country-level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Hydroxyzine Market Executive Summary

  • 1.1. Global Hydroxyzine Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Dosage Form (Tablets; Capsules; Injections; Syrups)
    • 1.3.2. By Route of Administration (Oral; Intramuscular)
    • 1.3.3. By Indication (Urticaria; Atopic Contact Dermatitis; Histamine-mediated Pruritus)
    • 1.3.4. By Distribution Channel (Hospital Pharmacies; Retail Pharmacies; Online Pharmacies)
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Hydroxyzine Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Provider Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory Frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Hydroxyzine Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rising incidence of atopic dermatitis and urticaria
    • 3.1.2. Expansion of pediatric and geriatric-friendly formulations
    • 3.1.3. Increased generic production and affordability
  • 3.2. Market Challenges
    • 3.2.1. Sedative and CNS side-effect profile
    • 3.2.2. Stringent regulatory usage guidelines for vulnerable populations
  • 3.3. Market Opportunities
    • 3.3.1. Advancements in drug delivery technologies
    • 3.3.2. Telehealth and online pharmacy distribution growth
    • 3.3.3. Adjunctive use in anxiety and sleep disorder management

Chapter 4. Global Hydroxyzine Market Industry Analysis

  • 4.1. Porter's Five Forces Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's Model
    • 4.1.7. Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economic
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunities
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Hydroxyzine Market Size & Forecasts by Dosage Form, 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Tablets Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 5.3. Capsules Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 5.4. Injections Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 5.5. Syrups Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 6. Global Hydroxyzine Market Size & Forecasts by Route of Administration, 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Oral Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 6.3. Intramuscular Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 7. Global Hydroxyzine Market Size & Forecasts by Indication, 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Urticaria Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 7.3. Atopic Contact Dermatitis Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 7.4. Histamine-mediated Pruritus Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 8. Global Hydroxyzine Market Size & Forecasts by Distribution Channel, 2022-2032

  • 8.1. Segment Dashboard
  • 8.2. Hospital Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 8.3. Retail Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 8.4. Online Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 9. Global Hydroxyzine Market Size & Forecasts by Region, 2022-2032

  • 9.1. North America Market
    • 9.1.1. U.S. Hydroxyzine Market
    • 9.1.2. Canada Hydroxyzine Market
  • 9.2. Europe Market
    • 9.2.1. UK Hydroxyzine Market
    • 9.2.2. Germany Hydroxyzine Market
    • 9.2.3. France Hydroxyzine Market
    • 9.2.4. Spain Hydroxyzine Market
    • 9.2.5. Italy Hydroxyzine Market
    • 9.2.6. Rest of Europe Hydroxyzine Market
  • 9.3. Asia Pacific Market
    • 9.3.1. China Hydroxyzine Market
    • 9.3.2. India Hydroxyzine Market
    • 9.3.3. Japan Hydroxyzine Market
    • 9.3.4. Australia Hydroxyzine Market
    • 9.3.5. South Korea Hydroxyzine Market
    • 9.3.6. Rest of Asia Pacific Hydroxyzine Market
  • 9.4. Latin America Market
    • 9.4.1. Brazil Hydroxyzine Market
    • 9.4.2. Mexico Hydroxyzine Market
    • 9.4.3. Rest of Latin America Hydroxyzine Market
  • 9.5. Middle East & Africa Market
    • 9.5.1. Saudi Arabia Hydroxyzine Market
    • 9.5.2. South Africa Hydroxyzine Market
    • 9.5.3. Rest of Middle East & Africa Hydroxyzine Market

Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
    • 10.1.1. Teva Pharmaceutical Industries Ltd.
    • 10.1.2. Dr. Reddy's Laboratories Ltd.
    • 10.1.3. Pfizer Inc.
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles
    • 10.3.1. Teva Pharmaceutical Industries Ltd.
      • 10.3.1.1. Key Information
      • 10.3.1.2. Overview
      • 10.3.1.3. Financial (Subject to Data Availability)
      • 10.3.1.4. Product Summary
      • 10.3.1.5. Market Strategies
    • 10.3.2. Cipla Ltd.
    • 10.3.3. Sun Pharmaceutical Industries Ltd.
    • 10.3.4. Sandoz International GmbH
    • 10.3.5. Glenmark Pharmaceuticals Ltd.
    • 10.3.6. Aurobindo Pharma Ltd.
    • 10.3.7. Mylan N.V.
    • 10.3.8. Apotex Inc.
    • 10.3.9. Hikma Pharmaceuticals PLC
    • 10.3.10. Torrent Pharmaceuticals Ltd.
    • 10.3.11. Taro Pharmaceutical Industries Ltd.
    • 10.3.12. Lupin Pharmaceuticals, Inc.
    • 10.3.13. Zydus Lifesciences Ltd.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!